Latest Content

The American Academy of Sleep Medicine’s first update since 2007 favors generic drugs, caffeine, light and naps, and advises against benzodiazepines.

People with advanced Parkinson’s disease who also have a sleep disorder cost about $50,000 a year to treat, $13,000 more than similar patients without one, according to an AbbVie-funded claims analysis.

Geisinger Health Plan President Jeremy Gaskill says the possibility that a growing number of patients won't have health insurance could put tremendous financial pressure on the plan's providers.

γδ T cells infiltrate small cell lung cancer tumors and can kill them without the MHC-I machinery these tumors typically switch off, and patients with more of them trended toward longer survival on anti-PD-L1 immunotherapy.

Upstream payment accuracy should reduce avoidable noise before it reaches those downstream functions.

The results come several months after the FDA approved Lisraya for dermatomyositis.

Psychedelic therapies are nearing FDA decisions, but people with HIV, many covered by Medicaid, have been left out of nearly all trials, commentary authors argue.

Christopher Stanley, M.D., MBA, says Henry Ford Health now projects its 2027 employee healthcare insurance premiums to increase half as much as what had been expected, partly because of Populance’s to bring about cost-effective care.

Rybrevant Faspro won accelerated approval for recurrent or metastatic HNSCC after a trial showed a 42% response rate in previously treated patients.

Researchers in Lyon, France, conducted a retrospective cohort study of intensifying the dosing of biologics such as Humira, adding oral antibiotics, or both as ways to boost the response of patients with hidradenitis suppurativa.

Expect Democrats to flex their oversight powers even if President Donald Trump’s veto power blocks their efforts to reverse Medicaid cuts or restore enhanced ACA subsidies. The administration’s most-favored-nation policies and HHS Secretary Kennedy will probably be in the hot seat.

Health plans should be using data, digital tools and human support to identify potential disruptions early, and whether a member is changing plans or managing a new health condition, the experience should feel guided rather than overwhelming.

Pretax adjusted income from operations from Express Scripts, Cigna's pharmacy benefit manager, fell by 21.5% compared with the third quarter of 2025, while income from operations of its specialty drug business jumped by 15%.

Annesha White, Pharm.D., M.S., Ph.D., and Fredrick Manasseh, Pharm.D., MBA, BCGP, explain where AI helps managed care pharmacy, where bias creeps in and what skills pharmacists need to oversee it.

Teva’s Weltruza delivers olanzapine monthly under the skin, with no loading doses, oral supplementation or post-injection monitoring required.

Value-based care has scored some cost-saving successes, says Christopher Stanley, M.D., MBA, president of Henry Ford Health's Populance. Health systems that build their own value-based care strategy, rather than adopting particular models one by one, will be in the best position to succeed, he says.

The second half of our conversation with Christopher Stanley, M.D., MBA, the president of Henry Ford Health's Populance and the newest member of the Managed Healthcare Executive editorial advisory board.

The first part of our conversation with Christopher Stanley, M.D., MBA, the president of Henry Ford Health's Populance and the newest member of the Managed Healthcare Executive editorial advisory board.

Unifying care management doubled patient outreach with the same staff, and virtual physical therapy is cutting costs, says Populance's Christopher Stanley, M.D.

Christopher Stanley, M.D., MBA, says Henry Ford Health's growth has led Populance to put its push for outside customers on hold and focus on its own system.

WHO advisers backed adding Oxford/Serum Institute of India and Moderna vaccine candidates to the Tumaini trial against the Bundibugyo Ebola strain.

Geisinger Health Plan President Jeremy Gaskill says being owned by a health system aligns incentives, cuts payer-provider busywork and speeds care to patients.

Geisinger Health Plan expects Medicaid enrollment to fall roughly 10% as H.R. 1 takes effect, President Jeremy Gaskill says, though the timing is still unclear.

As other insurers pull back, Geisinger Health Plan isn’t exiting any Medicare Advantage plans for 2027 and expects to grow, President Jeremy Gaskill says.

The second part of our interview with Jeremy Gaskill, the president of the Geisinger Health Plan. Gaskill discusses trends in the various segments of the health insurance market—Medicaid, Medicare Advantage, the employer-based commercial market and the ACA marketplace.

Democrats won Congress, but with Trump’s veto, their best healthcare tools are funding bills, hearings and bipartisan deals.

In the CONNECT trial, CGM users with type 2 diabetes not on insulin saw larger A1C reductions and more time in range than those using finger-stick testing.

CVS Health announced today that it is reorganizing into two publicly traded companies. The CEO spoke about working on "commercial agreements" between the two. Critics and competitors question how separate they will be.

South Dakota voters rejected Amendment I, which could have ended Medicaid expansion for approximately 31,000 residents if federal funding fell below 90%.

Christine Johnston says Medicaid plans have embraced biosimilars faster than commercial plans and challenges the idea that more expensive means better.

After more than 20 years at Humana, Jeremy Gaskill now leads nonprofit Geisinger Health Plan. The problems are the same, he says, the scale for solving them differs.